Betta Pharmaceuticals Partners with BioRay for Herceptin Biosimilar Anruize
China-based Betta Pharmaceuticals (SHE: 300558) announced a strategic partnership with fellow domestic firm BioRay Biopharmaceutical....
BioRay Pharmaceutical
Bioray Biopharmaceutical Expands to Turkey with Three Key Drugs, Marking International Milestone
Zhejiang Bioray Biopharmaceutical Co., Ltd. announced on March 31 that it has reached a collaboration...
BioRay Biopharmaceutical’s BR111 Receives NMPA Clearance for Clinical Trials in ROR1-Positive Malignancies
Zhejiang-based BioRay Biopharmaceutical has announced receiving clearance from the National Medical Products Administration (NMPA) to...
UCB Partners with BioRay Biopharmaceutical for Bimzelx Commercial Promotion in China
Belgium based UCB (EBR: UCB) is fulfilling its commitment to enhance attention to innovative products...
Fosun Pharmaceutical’s Humira Biosimilar Gains New Indications with NMPA Approval
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its biosimilar...
Fosun Pharmaceutical’s HanDaYuan Seeks NMPA Approval for Expanded Indications in Autoimmune Treatments
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that the National...
BioRay Pharmaceutical’s LIV-1 Targeted ADC BRY812 Files IND in China
Shanghai-based BioRay Pharmaceutical Co., Ltd has announced that an investigational new drug (IND) filing has...
BioRay Pharmaceutical’s Zuberitamab Approved by NMPA for CD20 Positive DLBCL Treatment
BioRay Pharmaceutical Co., Ltd has announced that its drug zuberitamab has been approved by the...